All Blogs
Oct 03, 2025
Shaping the Future of Ovarian Cancer Treatment: From PARP Inhibitors to ADCs
Ovarian cancer ranks among the most lethal gynecological cancers, largely because it is often detected at advanced stages and recurs frequently despite initial response to surgery and chemotherapy. Most cases are epithelial, with High-grade Serous Ovarian Cancer (HGSOC) being the most common and aggressive, typical...
Read More...
Oct 01, 2025
Wearables 2.0: The Next Wave of Clinical-Grade Wearable Medical Devices
Not long ago, the word wearable instantly brought to mind fitness trackers counting steps or smartwatches nudging users to stand up. While those devices sparked the early boom, the next chapter, Wearables 2.0, is unfolding at the intersection of healthcare and technology. Today, wearable medical devices are no long...
Read More...
Oct 02, 2025
Zimmer Biomet Secures Japan PMDA Approval for First Iodine-Treated Total Hip Replacement System; FluidAI Medical’s Origin™ Earns FDA 510(k) Clearance; Sky Labs Introduces CART BP; Forward Science Collaborates with Sage Dental to Launch PerioStōm; iotaMotion Sets New Benchmark with 1,000+ Cochlear Implant Procedures Using iotaSOFT®; Relief Cardiovascular Completes First Human Implant of Pioneering Smart Valve for Heart Failure Congestion
Zimmer Biomet Announced Japan PMDA Approval of World's First Iodine-Treated Total Hip Replacement System On September 25, 2025, Zimmer Biomet Holdings, Inc., a global leader in medical technology, announced that Japan’s Pharmaceutical and Medical Devices Agency (PMDA) had approved the iTaperloc® Complete a...
Read More...
Sep 30, 2025
Regeneron’s EVKEEZA Wins FDA Approval for HoFH in Children as Young as 1 Year; Eli Lilly’s INLURIYO Approved for ER+, HER2-, ESR1-Mutated Advanced Breast Cancer; Janssen’s TREMFYA Secures FDA Nod for Pediatric Plaque Psoriasis and Psoriatic Arthritis; Kedrion Biopharma’s QIVIGY Approved for Primary Humoral Immunodeficiency in Adults; Crinetics Pharma Wins FDA Approval for First Daily Pill, PALSONIFY, for Rare Growth Disorder
Regeneron’s EVKEEZA Wins FDA Approval for HoFH in Children as Young as 1 Year Regeneron Pharmaceuticals, Inc. announced that the FDA has approved EVKEEZA (evinacumab-dgnb) ANGPTL3 antibody, for children aged 1 to under 5 years with homozygous familial hypercholesterolemia (HoFH). This expands the indication from...
Read More...
Sep 29, 2025
Essential Thrombocythemia Treatment—Why the US Lags Behind Europe?
Affecting roughly 1–2 people per 100,000 each year, essential thrombocythemia is often silent, discovered during routine blood tests, yet it can quietly impact quality of life. The total number of diagnosed cases of essential thrombocythemia in the US was approximately 167,000 cases in 2024. In the United States, t...
Read More...
Sep 26, 2025
Leo’s ANZUPGO Cream: First FDA-Approved Treatment for Adults with Moderate-to-Severe Chronic Hand Eczema
Chronic hand eczema is more than just dry, itchy skin—it’s a persistent condition that affects up to 10% of adults worldwide, often interfering with daily life and work. Chronic hand eczema is characterized by either a persistent or relapsing course of hand eczema, or by eczema that does not respond to standard tre...
Read More...
Sep 25, 2025
Medtronic Gains FDA Clearance for Altaviva™ Device to Simplify Treatment of Urge Urinary Incontinence; FDA Grants Breakthrough Device Status to Virtuoso’s Surgical Robot; Lunit and Agilent Strike Partnership to Integrate AI into Biomarker-Based Diagnostics; QuidelOrtho Launches QUICKVUE Influenza + SARS Test for Clinical Use; Transpara® Breast AI Chosen to Power $16M PRISM Clinical Trial in the U.S.; IceCure Showcases ProSense® at CIRSE 2025 with Strong Clinical Evidence from 4 Independent Cryoablation Studies
Medtronic Secured FDA Approval for the Altaviva™ Device, Delivering a Simpler Experience in Treating Urge Urinary Incontinence On September 19, 2025, Medtronic plc, a global leader in healthcare technology, announced that it had received U.S. Food and Drug Administration (FDA) approval for the Altaviva™ de...
Read More...
Sep 24, 2025
Smart Inhalers: Redefining Respiratory Care with Technology and Data
The smart inhalers market has been rapidly evolving as digital health and connected medical devices gain traction worldwide. With increasing adoption of telemedicine, remote monitoring, and personalized healthcare, smart inhalers are emerging as a transformative solution for both patients and healthcare providers. ...
Read More...
Sep 23, 2025
Merck Wins FDA Approval for KEYTRUDA QLEX for Subcutaneous Use in Adults With Solid Tumors; Incyte Gains FDA Nod for OPZELURA Cream in Children Aged 2–11 With Atopic Dermatitis; Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome; MavriX Bio Secures FDA Fast Track for MVX-220 Gene Therapy in Angelman Syndrome; Biocon Biologics Gets FDA Approval for Denosumab Biosimilars BOSAYA and AUKELSO
FDA Approves Merck’s KEYTRUDA QLEX for Subcutaneous Use Across Multiple Solid Tumors Merck announced that the FDA has approved KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) for subcutaneous administration in adults across most of KEYTRUDA’s approved solid tumor indications. Unlike the intravenous...
Read More...
Sep 22, 2025
Sanofi’s WAYRILZ Approval Ushers in New Era for Immune Thrombocytopenia Treatment
Immune thrombocytopenia is a rare autoimmune disorder, affecting both children and adults. The global incidence of ITP is estimated at around 2–5 cases per 100,000 people annually, with prevalence higher in adults and a slight female predominance. In 2024, the total cases of immune thrombocytopenia were approxim...
Read More...